Education
About Us
Working with TipRanks
Follow Us
Cardax (CDXI)
OTHER OTC:CDXI
CDXI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.43 - $0.45
Previous CloseN/A
Volume610.00
Average Volume (3M)0.00
Market Cap
$80.00
Enterprise Value$0.00
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta115.92
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding802,516
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CDXI FAQ
What was Cardax’s price range in the past 12 months?
Cardax lowest stock price was $0.43 and its highest was $0.45 in the past 12 months.
What is Cardax’s market cap?
Cardax’s market cap is $80.00.
When is Cardax’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cardax’s earnings last quarter?
Cardax released its earnings results on May 14, 2021. The company reported -$1.74 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.74.
Is Cardax overvalued?
According to Wall Street analysts Cardax’s price is currently Overvalued.
Does Cardax pay dividends?
Cardax does not currently pay dividends.
What is Cardax’s EPS estimate?
Cardax’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cardax have?
Cardax has 802,516 shares outstanding.
What happened to Cardax’s price movement after its last earnings report?
Cardax reported an EPS of -$1.74 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cardax?
Currently, no hedge funds are holding shares in CDXI
Company Description
Cardax
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.
Technical Analysis
Biodexa Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Ocean Biomedical
―
Onconetix
―